Literature DB >> 21516025

Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration.

Femke A E Lambers1, Kees Brinkman, Janke Schinkel, Ingrid J B Spijkerman, Richard Molenkamp, Roel A Coutinho, Maria Prins, Jan T M van der Meer.   

Abstract

We evaluated hepatitis C virus (HCV) treatment and the effect of treatment duration (24 versus 48 weeks) on treatment outcome among 50 HIV-infected men who have sex with men with acute HCV infection in Amsterdam. Overall sustained virological response (SVR) rate was 76%. Treatment duration was not significantly associated with SVR (adjusted odds ratio = 2.32; 95% confidence interval 0.39-13.97), suggesting that 24-week treatment may be sufficient for acute HCV infection in HIV-coinfected patients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21516025     DOI： 10.1097/QAD.0b013e3283480144

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Acute HCV in HIV-infected MSM: modes of acquisition, liver fibrosis, and treatment.

Authors:  Emma Kaplan-Lewis; Daniel Seth Fierer
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

2.  Characterization of Hepatitis C Virus (HCV) Envelope Diversification from Acute to Chronic Infection within a Sexually Transmitted HCV Cluster by Using Single-Molecule, Real-Time Sequencing.

Authors:  Cynthia K Y Ho; Jayna Raghwani; Sylvie Koekkoek; Richard H Liang; Jan T M Van der Meer; Marc Van Der Valk; Menno De Jong; Oliver G Pybus; Janke Schinkel; Richard Molenkamp
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

Authors:  Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol
Journal:  Clin Infect Dis       Date:  2013-12-13       Impact factor: 9.079

Review 4.  Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases.

Authors:  Giovanni B Gaeta; Massimo Puoti; Nicola Coppola; Teresa Santantonio; Raffaele Bruno; Antonio Chirianni; Massimo Galli
Journal:  Infection       Date:  2017-12-13       Impact factor: 3.553

Review 5.  Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.

Authors:  Lynn E Taylor; Tracy Swan; Gail V Matthews
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

6.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

7.  The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic.

Authors:  Lynn E Taylor; Julie A Foont; Allison K DeLong; Alysse Wurcel; Benjamin P Linas; Stacey Chapman; Michaela A Maynard; Susan Cu-Uvin; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2014-01       Impact factor: 5.078

Review 8.  Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.

Authors:  David L Wyles; Mark S Sulkowski; Douglas Dieterich
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079

Review 9.  Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.

Authors:  Bing Zhang; Nghia H Nguyen; Brittany E Yee; Benjamin Yip; Walid S Ayoub; Glen A Lutchman; Mindie H Nguyen
Journal:  Intervirology       Date:  2015-09-25       Impact factor: 1.763

10.  Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.

Authors:  Masahiro Ishikane; Koji Watanabe; Kunihisa Tsukada; Yuichi Nozaki; Mikio Yanase; Toru Igari; Naohiko Masaki; Yoshimi Kikuchi; Shinichi Oka; Hiroyuki Gatanaga
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.